Rowell Emily A, Wang Liqing, Hancock Wayne W, Wells Andrew D
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
J Immunol. 2006 Oct 15;177(8):5169-76. doi: 10.4049/jimmunol.177.8.5169.
The cyclin-dependent kinase (CDK) inhibitor p27kip1 is an important negative regulator of the cell cycle that sets a threshold for mitogenic signals in T lymphocytes, and is required for T cell anergy in vitro. To determine whether p27(kip1) is required for tolerance in vivo, we performed cardiac allograft transplantation under conditions of combined CD28/CD40L costimulatory blockade. Although this treatment induced long-term allograft survival in wild-type recipients, costimulatory blockade was no longer sufficient to induce tolerance in mice lacking p27kip1. Rejected allografts from p27kip1-/- mice contained more CD4+ T lymphocytes and exhibited more tissue damage than allografts from tolerant, wild-type mice. Infiltrating p27kip1-deficient T cells, but not wild-type T cells, exhibited nuclear expression of cyclins E and A, indicating uncontrolled T cell cycle progression in the graft. The failure of tolerance in p27kip1-/- mice was also accompanied by markedly increased numbers of allospecific, IFN-gamma-producing cells in the periphery, and occurred despite apparently normal regulatory T cell activity. These data demonstrate that the CDK inhibitor p27kip1 enforces the costimulatory requirement for the expansion and differentiation of alloimmune effector T lymphocytes in vivo, and point to CDKs as novel targets for immunosuppressive or tolerance-inducing therapies.
细胞周期蛋白依赖性激酶(CDK)抑制剂p27kip1是细胞周期的重要负调控因子,它为T淋巴细胞中的促有丝分裂信号设定阈值,并且在体外T细胞无反应性中是必需的。为了确定p27(kip1)在体内耐受中是否必需,我们在联合CD28/CD40L共刺激阻断的条件下进行了心脏同种异体移植。尽管这种治疗在野生型受体中诱导了长期的同种异体移植存活,但共刺激阻断在缺乏p27kip1的小鼠中不再足以诱导耐受。来自p27kip1-/-小鼠的被排斥的同种异体移植物比来自耐受的野生型小鼠的同种异体移植物含有更多的CD4 + T淋巴细胞,并且表现出更多的组织损伤。浸润的p27kip1缺陷型T细胞而非野生型T细胞表现出细胞周期蛋白E和A的核表达,表明移植物中T细胞周期进展不受控制。p27kip1-/-小鼠的耐受失败还伴随着外周血中同种异体特异性、产生IFN-γ的细胞数量明显增加,并且尽管调节性T细胞活性明显正常,但仍发生了这种情况。这些数据表明,CDK抑制剂p27kip1在体内强化了同种异体免疫效应T淋巴细胞扩增和分化的共刺激需求,并指出CDK作为免疫抑制或诱导耐受疗法的新靶点。